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1158-71 Cardiac-Specific Gain-of-Function Mutation in the 
Natriuretic Peptide A Receptor Is Associated With 
Improved Diastolic Function in Presence and Absence 
of Pressure Overload Hypertrophy 
1158-73 Altered Angiotensin II-Induced Activation of 
Intracellular Signalling Pathways in Failing Human 
Ventricular Myocytes 
Allison M. Pritchett. Maria L. Valencik. John A. McDonald, Gerald E. Harder% Margaret 
M. Redfield. Mayo Clinic Foundation, Rochester, MN, Salt Lake City Veterans 
Administration Medical Center, Salt Lake City, UT 
Pietro A. Modesti Alessandra Modesti, Simone Vanni, Thomas Toscano, llxa Cecioni, 
Tania Gamberi, lacopo Bertoloui, Massimo Maccherini, GianGastone Neri Serneri, 
University of Florence, Florence, Italy 
Background: Few therapies are known to enhance diastolic function. Systemic adminis- 
tration of natriuretlc peptldes (NP) improves diastolic function. However, this may be due 
to effects on load, rather than a direct myocardlal action. We generated mice with acar- 
disc-specific (a-MHC promoter) gain-of-function mutation (GoF, HCAT E974A) in the 
natriuretic peptide A receptor (NPRA) resulting in myocyte-specific constitutive NPRA 
activation. We hypothesized that GoF mice would exhibit enhanced diastolic function and 
develop less diastolic dysfunction with pressure-overload. 
Methods: GoF mice (n=l2) and their wildtype (WT -/-, n=18) littermates underwent 
abdominal aortic banding to generate pressure-overload hypertrophy. LV structure and 
function (echo, catheterization, autopsy) were assessed three weeks after banding. Non- 
banded GoF (n=15) and Wl -/-(n=l3) groups ware controls. 
Results: See table (mean *SD): With aortic banding, both GoF and WT mice developed 
LV hypertrophy. While load and systolic function were similar between Wl and GoF mice 
without and with banding, the time constant of LV relaxation (Tau) was decreased in GoF 
mice as compared to WT indicating improved diastolic function. 
Conclusion: Chronic cardiac-specific NPRA activation via this GoF mutation enhanced 
diastolic function in mice and markedly attenuated diastolic dysfunction associated with 
pressure-overload hypertrophy. These data suggest that NP improve diastolic function 
via a direct myocardial effect. 
Background The enhanced cardiac angiotensin (Ang) II production in human failing ven- 
tricles is associated with an Increased expression of proinflammatory cytokines. We 
assessed the hypothesis that in failing myocytes the Ang II evoked signalling is read- 
dressed versus the activation of intracellular signaling not elicited in the normal heart. 
Methods Studies were performed on isolated ventricular myocytes (1x10s celVml) 
obtained from 12 heart failure patients who underwent cardiac transplantation and 5 ten- 
tative heart donors. The activation of intracellular kinase pathways (ERKl/P, SAPWJNK 
and JAKP) by Ang II (10 nM) in the presence or in the absence of type 1 (valsartan, 1 ~.IM) 
and type 2 (PDl23319. 1pM) receptor antagonlsts, was investigated by Western blot 
analisis using specific antibodies. 
Results In non failing myocytes Ang II type 1 receptor stimulation significantly activated 
mainly ERKlR and also SAPWJNK pathways but no JAK2 phosphorilation was 
observed. JAKP phosphorilation was induced only by interleukin-8 (100 ng/ml). 
In failing myocyies Ang II mediated ERKlI2 activation was selectively impaired (-88% vs 
controls) with unchanged SAPWJNK stimulation. Differently from controls, in failing myo- 
cytes Ang II caused a significant type 1 receptor mediated increase in JAK2 phosphorila- 
tion. 
Conclusion In conclusion, in falling myocytes Ang II activates different intracellular path- 
ways from normal cells as indicated by the impaired Ang II mediated activation of the 
growth promoting (ERKlI2) signalling with contemporary enhanced activation of the 
proinflammatory (JAK2) pathway. 
Variable HCAT E Control HCAT E Banded 
LV End-diastolic 
dimension, mm 
Fractional Shortening, % 
LV Mass, g 
Heart Rate (anesthesia), 
bpm 
Maximum LV Pressure. 
mmHg 
End-diastolic LV 
Pressure, mmHg 
Tau, msec 
Heart weight I Body 
weight, mg/g 
GoF Littermate P GoF Littermate P 
(+I-) (-I-) Value (+I-) (-I-) VaIlIs 
3.5eO.2 3.4r0.4 0.45 3.7ztO.3 3.5r0.2 0.03 
36*5 34*4 
0.09+0. 0.09*0.02 
02 
450&O 398*45 
94*14 84+14 
6*6 5*6 0.58 7*8 8+5 0.60 
13*2 16i3 0.04 16i4 21*5 
4.2eO.3 4.leO.3 0.36 4.8*1 .O 4.5eO.5 
0.33 
0.55 
0.04 
0.25 96+15 86+12 
33*4 34*3 
0.12*0. 0.11*0.01 
03 
409*72 399*83 
0.89 
0.49 
0.78 
0.07 
0.04 
0.30 
1158-72 Chronic Al and A2b Adenosine Receptor Blockade 
Improves Diabetes and Attenuates Renal and Cardiac 
Histopathology in Animals With the Metabolic 
Syndrome 
Steven P. Tofovic, Eman M. Salah. Glenn Smits, Eric Whalley, Barry Ticho, Edwin K. 
Jackson University of Pittsburgh School of Medicine, Pittsburgh, PA, Biogen, Inc.. -1 
CambrIdge, MA 
Background: In animals and patients with left ventricular dysfunction, short-term Al ade- 
nosine receptor (Al R) blockade causes diuresislnatriuresls without altenng potassium 
excretion and, in contrast to loop diuretics, improves renal function. A2b adenosine 
receptor (A2bR) blockade has an anti-diabetic effect. The purpose of the present study 
was to examine the long-term effects of AlWA2bR blockade in an animal system 
designed to model the complex pathology that characterizes, wtth increasing frequency, 
the modern cardiac patient. 
Methods: BG9928 is a novel, orally active and selective adenoslne receptor antagonist 
which has high affinity for Al R and moderate affinity for A2bR. The ZSFl rat IS a model 
of the metabolic syndrome that expresses obesity, hypertension, type II diabetes, dyslip- 
Idemra, dilated cardiomyopathy and severe nephropathy. BG9928 (10 mg/kgIday). capto- 
pril (100 mglkglday. orally) and furosemide (50 mglkgfday, orally), alone or in 
combination, ware administered for 24 weeks to ZSFl rats (9 or 10 par group). An 
untreated control group was included. 
Results: BG9928 reduced urinary glucose excretion (from 823 +I- 179 to 196 +/- 80 mg/ 
kg/day; P=O.O04) and in some groups attenuated worsening of the oral glucose tolerance 
test and increases in fasting plasma glucose and insulin levels. Chronic captopril doubled 
the urinary excretion rate (P<O.OOl) and the renal interstitial levels (P=O.OOE) of adenos- 
inc. Compared with control animals, BG9928 blocked the age-related increase in plasma 
triglycerides and significantly reduced focal segmental glomerulosclerosis and cardiac 
vasculitisiinflammation. degenerative ischemic changes and necrosis (P<O.O5). At 12 
weeks of treatment, BG9928 Increased captopril- and furosemide-induced ranln release, 
but this effect was lost by 24 weeks into treatment. 
Conclusion: In dilated cardiomyopathy complicated by the metabolic syndrome and renal 
disease, chronic AiR/APbR blockade may improve type II diabetes, lower plasma tnglyc- 
erides and attenuate renal and cardiac histopathology. 
1158-74 New Technique for Measurement of Lefi Ventricular 
Pressure in Conscious Mice: Detection of Persistent 
Hemodynamic Depression for Three Days Post 
Anesthesia 
Shinli Ishlzaka, Richard E. Sievers, Bo-Qtng Zhu, Elyse Foster, Paul C. Simpson, William 
Grossman, University of California San Francisco. San Francisco, CA 
Background: Physiologic studies in transgenic and knockout mice have largely been 
done under anesthesia. Concern about the effects of anesthesia on physiologic mea- 
surements lad us to develop methodology to assess left ventricular (LV) pressure in con- 
SCIOUS mkx?. This studv was desianed to evaluate the new techniaue. and to assess 
acute and persistent effects of anesthesia on LV function in mice.Methcds: PE-50 tub- 
ina filled with heoarinized saline was imolanted in the LV cavitv throuah its aoex via an I 
L  1  
abdominal approach, and exteriorized to the back. This surgery was done under anes- 
thesia with either intraperitoneal injection of k&amine (EOmg/kg) and xylazine (5mg/kg) 
(K+X) in 11 mice or isoflurane (ISF. 1.5 ~01%) by inhalation in 14 mice. Post-operatively, 
mice were trained daily to lie quietly head first in a plastic cone. LV pressure, dP/dt and 
heart rate (HR) in conscious state were compared between the two groups at 3 days and 
1 week following recovery from surgery using a 1.4 F Millar catheter inserted into the LV 
through the tubing with mice lying quietly in the plastic cone. Results: Acutely during 
anesthesia, K+X decreased heart rate (HR) from 698 to 298 bpm (pcO.Ol), LV pressure 
from 107 to 85 mmHg (pcO.01) and maxlmal dP/dt (dP/dh,d from 15,724 to 4,445 
mmHg/sec (p<O.Ol). Moreover, these negative chronotropic and negative inotropic 
effects of K+X were significantly greater than those of ISF. HR and dP/dh,,, were signifi- 
cantly decreased in K+X mice 3 days after surgery compared to ISF (655 vs. 711 bpm; 
~~0.05. 14,448 vs. 18,048 mmHg/sec; p<O.OOl, respectively), and Increased to the same 
level as in ISF mice 1 week after surgery (698 bpm; ns vs. ISF, 17,230 mmHg/sec; ns vs. 
ISF, respectively). In ISF mice, recovery of function occurred rapidly and there were no 
differences in LV variables between 3 days and l-week. Conclusions: LV pressure and 
its derivative can be measured in conscious mice with a catheter inserted through tubing 
implanted permanently in the LV apex. Anesthesia with either K+X. or to a lesser extent 
ISF, depressed LV function acutely. This depression of function perslsted for 3 days after 
surgery with K+X (but not ISF) and did not recover completely until 1 week post-anesthe- 
sia. 
1158-75 Augmenting Renal Function in Experimental 
Congestive Heart Failure by Brain Natriuretic Peptide 
and Lasix 
Alessandro Cataliottb Horng H. Chen, Guide Boerrigter. Lisa C. Costello-Boerrigter, 
Toshihiro Tsuruda, Lorenzo S. Malatino. John C. Burnett, Jr., Mayo Clinic and 
Foundation, Rochester, MN 
Background: Congestive heart failure (CHF) is characterized by avid sodium and water 
retention. While loop diuretics are powerful natriuretic agents, they can reduce glomeru- 
lar filtration rate (GFR) and activate the renin-anglotensin-aldosterone system (RAAS). 
Studies have reported that GFR is a key predictor of mortality in CHF. Therefore, new 
therapeutic strategies are warranted to both minimize side effects of conventional diuret- 
ics and to potentiate their renal actions. Brain natriuretic peptide (BNP) has natriuretic 
and renln inhibiting properties. The diuretic actions of BNP, mainly located in the tubules, 
are associated with preserved GFR. We characterized the renal actions of BNP alone 
and in combination with Lasix (L). We hypothesized that BNP in combination with L main- 
tains GFR and suppresses RAAS. 
Methods: CHF was produced I” two groups of dogs by rapid ventricular pacing (10 days 
at 240 bpm). At day 11 one group received continuous (30 m!n) intravenously adminis- 
tered low dose (2 pmollkglmin) followed by 30 min high dose (10 pmollkg/min) of BNP. A 
second group (BNP+L) of dogs received i.v. co-infusion (60 min) of L (Img/Kg/hr) and 
low and high dose of BNP. ’ Indicates ~~0.05 vs baseline. 
TIMP-1 quartiles 01 (12 Q3 Q4 P (trend) 
LV mass, g 166 166 166 171 0.36 
LV wall thickness, cm 1.93 1.91 1.93 1.96 0.50 
LVESD, cm 2.94 3.01 2.99 3.03 0.03 
LVFS,% 37.9 37.0 37.0 36.3 0.003 
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Results: There were no differences in hemodynamic actions between groups. BNP 
increased urinary flow (from baseline 0.12 ~0.03 to low 0.76t0.82’ and high dose 
1.2OiO.96’ mifmin), but the effect of BNP+L was significantly (pcO.0001) higher (from 
0.12 kO.03 to 7.10+1.21’ and 6.25+0.94’ mUmin). Similarly, urinary sodium excretion 
(BNP: from 2.23*1.73 to 83.74+131.37’ and 164.66*171.05* mEq/min: BNP+L: from 
1.46+0.61 to 666.66i176.44’ and 606.41+65.96^ mEq/min) was significantly higher in 
BNP+L group (p<O.OOOl). GFR was maintained in both groups and plasma renin activity 
and aldosterone were not activated. 
Conclusion: BNP and BNP+L had similar beneficial hemcdynamic actions. Importantly, 
with a profound natriuretic and diuretic response with BNP+L, GFR was maintained with 
no activation of RAAS. Co-administration of BNP and a loop diuretic may be beneficial in 
preserving renal function and inhibiting the activation of aldosterone while maximizing 
natriuresis and diuresis. 
lar dyssynchrony (difference in LV and right ventricular (RV) mean phase angles) did not 
change from baseline to the final visit in the PL group (11 i17 vs 12 +9), while it 
improved in the cawedilol group (13 +17 vs 9 *14: p<O.Ol). The degree of intraventricu- 
lar dyssynchrony (std deviation of the mean phase angle) significantly improved for LV in 
the carvedilol group (54 i16 vs 51 *19: p=O.O4), but did not change for both the RV (41 
i12 vs 41 ill) and the LV (57 214 vs 56 +19) in the PL group, and for the RV in the 
carvedilol group (40 +14 vs 30 210). Conclusion: Treatment with calvedilol in patients 
with ischemic cardiomyopathy improves interventricular contractile synchrony between 
the LV and RV and intraventricular contraction synchrony of the LV. This is a new and 
additional mechanism by which cawedilol exerts beneficial effects on left ventricular 
function in ischemic heart failure. 
POSTER SESSION 
1159MP Moderated Poster Session...Ventricular 
Remodeling 
Tuesday, April 01, 2003, 9:00 a.m.-l 1:OO a.m. 
McCormick Place, Hall A 
9:oo a.m. 
1159MP-163 Tissue inhibitor of Metalloproteinases-1 in Plasma-- 
Relation to Left Ventricular Function and Geometry: The 
Framingham Heart Study 
JohanSundstrom, Emelia J. Benjamin, Jane Evans. Daniel Levy, Martin Larson, Douglas 
Sawyer, Deborah Siwik, Wilson Colucci. Peter W. Wilson, Ramachandran S. Vasan, 
FramIngham Heart Study, Framingham, MA 
Background: Tissue inhibitor of metalloproteinases-1 (TIMP-1) is a key regulator of car- 
diac extracellular matrix remodeling. Plasma TIMP-1 has been associated with hyperten- 
sion, left ventricular (LV) hyperirophy and heart failure in small, selected referral 
samples. Because of its role in LV remodeling, we examined the relations of total plasma 
TIMP-1 (free and in complex with metalloproteinases) to cardiac function and geometry 
in participants of the Framingham Heart Study. Methods: We studied 1014 participants 
(mean age 56 years, 59% women) free of heart failure and previous myocardial infarction 
who underwent routine echocardiography. 
Results: Plasma TIMP-1 was related positively to LV mass, LV wall thickness, end-sys- 
tolic diameter (LVESD), and left atrial diameter but inversely to fractional shortening (FS) 
in linear regression models adjusting for age, sex and height. Addiiional adjustment for 
weight, systolic blood pressure, antihypertensive treatment, diabetes, heart rate, smok- 
ing and total-IHDL-cholesterol ratio anew&d the relations of plasma TIMP-1 to LV 
mass, wall thickness, and left atrial diameter. In the latter models, inverse relations of 
plasma TIMP-1 to LVFS and direct relations to LVESD were maintained. 
Plasma TIMP-1 and LV measures 
LV measures are least squares means adjusted for age, sex, height, weight, systolic 
blood pressure, antihypertensive treatment, diabetes, heart rate, smoking and total-l 
HDL-cholesterol ratio 
Conclusion: In our large community-based sample free of heart failure and previous 
myocardial infarction, total plasma TIMP-1 was inversely related to LVFS independently 
of traditional cardiovascular risk factors, perhaps because it is a marker of LV remodel- 
ing. 
1159MP-164 Effect of Carvedilol to Correct Interventricular 
Dyssynchrony in Patients Wlth Chronic Heart Failure 
Due to lschemic Lefl Ventricular Systolic Dysfunction: 
Results of the CHRISTMAS Study 
9:12 a.m. 
J~CODO Dalle Mule, John G F. Cleland. Dudley J. Pennel, Renzo Perelli. Gordon Murray, 
Andrew J S. Coats, Simon Ray, Avijlt Lahiri. Peter W. Macfarlane, Zvi Vered. City 
Hospital, Pieve di Cadore, Italy. Royal Brompton Hospital, London, United Kingdom 
Objective: To measure ventricular contractile synchrony in patients with ischemic left 
ventricular (LV) systolic dysfunction and to evaluate the effects of carvedilol on contrac- 
tile synchrony. Methods: We measured intraventricular conduction delay by means of 
phase analysis in 164 patients of the CHRISTMAS Study, who underwent radionuclide 
ventriculography (RNVG) at the time of randomization and at the end of the maintenance 
phase of treatment with cawedilol or placebo (PL). Results: The degree of intewentricu- 
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1159MP-165 Early Heightened inflammation Promotes Greater Left 
Ventricular Remodeling Following Anterior Myocardial 
Infarction 
Paul T. Vaitkus Ray S. Clemmer, Robert J. Anders, Johann Bauersachs, Jan B&as, Jiri 
Krupicka, University of Illinois et Chicago, Chicago, IL 
Background and Aims:Elevated inflammatory markers following MI predict poorer prog- 
nosis. The relationship of inflammation and LV remodeling has not been explored. Our 
hypothesis was that heightened inflammation would be related to greater LV dilation after 
MI. Methods:64 pts at 17 centers with a first anterior ST-elevation Ml completed sequen- 
tial contrast-enhanced echoes. Serum levels of IL-6 and TNF-a were measured 3-36 
hours (baseline) and 7 days after onset of Ml. Pts were divided into terciles of IL-6 and 
TNF-a for comparisons of the degree of increase in LVEDA from baseline to Day 
PB.Results:Baseline IL-6, but not TNF-a was associated with the degree of remodeling 
(see Fig). Pts in the highest tercile of IL-6 levels at baseline exhibited a greater degree of 
LV dilation. At day 7, most pts had undetectable IL-6 levels. Pt with elevated IL-6 at Day 
7 had greater remodeling (increase of LVEDA of 7 vs 2 cm2;p<.Ol)Conclusions: Height- 
ened inflammation early after Ml is associated with greater LV dilation, suggesting both a 
pathophysiologic link and a target for intervention. 
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1159MP-166 Left Ventricular Remodeling Is the Most Common 
Cause of Systolic Dysfunction After Acute Myocardial 
Infarction: Flndings From the Stent-PAMI Study 
Kishore J. Hariai, Cindy L. Grines, Steve Manichak. Judith A. Boura. Gregg W. Stone, 
David Cox, Bruce R. Brodie, William ONeill, William Beaumont Hospital, Royal Oak, Ml 
Background: Len ventricular systolic dysfunction (LVSD) develops after AMI in some 
patients despite reperfusion therapy and could be due to delayed or unsuccessful reper- 
fusion, silent ischemia. recurrent ischemic events, or left ventricular remodeling. The pur- 
pose of this study was to evaluate the frequency and etiology of LVSD following AMI 
treated with primary angioplasty (PCI). 
Methods: We studied 415 patients from the Stem-PAM1 study who underwent PCI with 
or without stent implantation, and had protocol-driven core lab assessment of LV ejection 
fraction (LVEF) acutely and 6-months later. We defined LVSD as a decrease in LVEF of 
210% at 6-months. We compared reperfusion delay, incidence of successful reperfusion 
(final stenosis < 30% with TIMI- flow), multivessel disease (reflecting propensity for 
ischemia at a distance), B-moo reinfarction @e-MI), and 6-mon target vessel revascular- 
i&ion (TVR) in patients with and without LVSD. 
Results: LVSD developed in 73 (16%) patients. Patients with LVSD were more likely to 
be male (69 vs 75%), had higher baseline LVEF (59 vs 53%, pcO.OOOl), but otherwise 
similar clinical and angiographic characteristics. Chest pain onset-to-door time (152 vs 
156 mini. door-to-balloon time (149 YS 173 min). successful reoerfuslon (61 vs 76%). 
multives~el disease (45 YS 50%): 6-mon re-MI (2.; vs 2.1%) and &non TVd (14 vs 12%) 
were similar lo>0.05 for all) in oatients with and without LVSD. At 6-months. LVEF was 
lower (47 vs 61%, p<O.OOOl), but LV end-diastolic volume (163+/-73 vs 140+/-62, 
p=O.OOS) and end-systolic volume (86+/-50 vs 55+/-32, pcO.0001) were higher in patients 
with LVSD. 
Conclusions: 1. LVSD develops unpredictably in a substantial minority of patients with 
AMI despite PCI. 2. Since LVSD is not related to delayed or unsuccessful reperfusion, 
multivessel disease, or recurrent ischemic events, it is likely caused by adverse LV 
remodeling. 3. Our findings support the routine use of ACE-inhibitors and beta-blockers 
for preservation of LV function after successful primary PCI. 
